Langer-backed Kala scores $90M IPO as it lines up a pair of NDAs
Kala Pharmaceuticals has now joined the ranks of this year’s biotech IPO class, hitting the range and raising $90 million after pricing shares at $15.
That cash will now help fund the final leg of two Phase III studies for two different doses of KPI-121 and the first round of commercialization work that the biotech hopes lies ahead. Their lead drug is being studied for inflammation and pain following ocular surgery as well as the temporary relief of the signs and symptoms of dry eye disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.